tiprankstipranks
Advertisement
Advertisement

TNYA Stock Latest News

Buy Rating Reiterated on Tenaya: Promising TN-401 RIDGE-1 Data, Strong Transgene Expression, and Upcoming Catalysts Support Attractive Risk/Reward
RatingsBuy Rating Reiterated on Tenaya: Promising TN-401 RIDGE-1 Data, Strong Transgene Expression, and Upcoming Catalysts Support Attractive Risk/Reward
3d ago
TNYA
Tenaya reports data from RIDGE-1 Phase 1b/2 clinical trial of TN-401
PremiumThe Fly
Tenaya reports data from RIDGE-1 Phase 1b/2 clinical trial of TN-401
5d ago
TNYA
Tenaya Therapeutics: Buy Rating Reiterated on Upcoming Gene Therapy Catalysts and Unchanged $5 Price Target
PremiumRatings
Tenaya Therapeutics: Buy Rating Reiterated on Upcoming Gene Therapy Catalysts and Unchanged $5 Price Target
13d ago
TNYA
Tenaya Therapeutics reports Q1 EPS (9c), consensus (9c)
PremiumThe Fly
Tenaya Therapeutics reports Q1 EPS (9c), consensus (9c)
14d ago
TNYA
Tenaya Therapeutics Duchenne muscular dystrophy treatment granted orphan status
PremiumThe Fly
Tenaya Therapeutics Duchenne muscular dystrophy treatment granted orphan status
1M ago
TNYA
Tenaya’s TN-401: Differentiated PKP2 Gene Therapy Opportunity Underpins Favorable Risk–Reward and Buy Rating
PremiumRatingsTenaya’s TN-401: Differentiated PKP2 Gene Therapy Opportunity Underpins Favorable Risk–Reward and Buy Rating
1M ago
TNYA
Advancing Pipeline and Regulatory Clarity Underpin Buy Rating on Tenaya Therapeutics
Premium
Ratings
Advancing Pipeline and Regulatory Clarity Underpin Buy Rating on Tenaya Therapeutics
2M ago
TNYA
Tenaya Therapeutics: Early Gene Therapy Promise, Cash Runway to 2H27, and 2026 Data Catalysts Support Buy Rating and $5 Target
Premium
Ratings
Tenaya Therapeutics: Early Gene Therapy Promise, Cash Runway to 2H27, and 2026 Data Catalysts Support Buy Rating and $5 Target
2M ago
TNYA
Tenaya Therapeutics: Gene Therapy Momentum and De‑Risking Clinical Milestones Support Buy Rating
PremiumRatings
Tenaya Therapeutics: Gene Therapy Momentum and De‑Risking Clinical Milestones Support Buy Rating
2M ago
TNYA
Tenaya Therapeutics reports Q4 EPS (12c), consensus (12c)
PremiumThe Fly
Tenaya Therapeutics reports Q4 EPS (12c), consensus (12c)
2M ago
TNYA
3 Best Stocks to Buy Now, 3/10/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 3/10/2026, According to Top Analysts
2M ago
EVAX
IMRX
TN-301: Differentiated HDAC6 Inhibitor Offering Dual Skeletal and Cardiac Benefit in DMD with Multiple Near-Term Catalysts
PremiumRatings
TN-301: Differentiated HDAC6 Inhibitor Offering Dual Skeletal and Cardiac Benefit in DMD with Multiple Near-Term Catalysts
2M ago
TNYA
Tenaya Therapeutics presents preclinical data evaluating TN-301
PremiumThe FlyTenaya Therapeutics presents preclinical data evaluating TN-301
2M ago
TNYA
Tenaya Therapeutics: Alnylam Partnership Validates Cardiovascular Platform and Supports Long-Term Buy Thesis
Premium
Ratings
Tenaya Therapeutics: Alnylam Partnership Validates Cardiovascular Platform and Supports Long-Term Buy Thesis
3M ago
TNYA
Tenaya Therapeutics: Alnylam Collaboration De-Risks Platform and Expands Cardiovascular Upside, Supporting Buy Rating
Premium
Ratings
Tenaya Therapeutics: Alnylam Collaboration De-Risks Platform and Expands Cardiovascular Upside, Supporting Buy Rating
3M ago
TNYA
Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration
PremiumCompany Announcements
Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration
3M ago
8K
TNYA
Tenaya Therapeutics enters research collaboration with Alnylam
PremiumThe Fly
Tenaya Therapeutics enters research collaboration with Alnylam
3M ago
ALNY
TNYA
e.l.f., Crown Castle, DoorDash, Stag, Tenaya Shake-Up
PremiumWeekend Updates
e.l.f., Crown Castle, DoorDash, Stag, Tenaya Shake-Up
3M ago
CCI
ELF
Tenaya Therapeutics Faces Nasdaq Deficiency, Amends Equity Plan
PremiumCompany Announcements
Tenaya Therapeutics Faces Nasdaq Deficiency, Amends Equity Plan
4M ago
8K
TNYA
Tenaya Therapeutics: 2026 Clinical Milestones, FDA Pivotal Pathway, and Strengthened Balance Sheet Support Buy Rating
PremiumRatingsTenaya Therapeutics: 2026 Clinical Milestones, FDA Pivotal Pathway, and Strengthened Balance Sheet Support Buy Rating
4M ago
TNYA
Tenaya Therapeutics: 2026 as a Pivotal Year for TN-201 and TN-401 Clinical Readouts and Regulatory De-Risking Supporting a Buy Rating
Premium
Ratings
Tenaya Therapeutics: 2026 as a Pivotal Year for TN-201 and TN-401 Clinical Readouts and Regulatory De-Risking Supporting a Buy Rating
4M ago
TNYA
Tenaya Therapeutics announces 2026 strategic priorities
Premium
The Fly
Tenaya Therapeutics announces 2026 strategic priorities
4M ago
TNYA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >